Keros Therapeutics, Inc. (KROS) vs Prelude Therapeutics Incorporated (PRLD)
A side-by-side comparison of Keros Therapeutics, Inc. and Prelude Therapeutics Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
KROS
Keros Therapeutics, Inc.
$11.28HealthcareDelayed quote: Oct 6, 2026, 12:14 PM EDT
PRLD
Prelude Therapeutics Incorporated
$3.76HealthcareDelayed quote: Oct 6, 2026, 12:15 PM EDT
Total return — KROS vs PRLD
growth of $100 · dividends reinvested · last 6yKROS -71.6% (-18.9%/yr)PRLD -85.6% (-27.6%/yr)KROS compounded faster over this window
KROS PRLD
KROS vs PRLD: by the numbers
- •KROS is the larger company ($224M vs $214M market cap).
- •Both run net losses; PRLD's is the smaller (-269.75% vs -553.88% net margin).
Metrics side by side
Valuation
| Metric | KROS | PRLD |
|---|---|---|
| P/S ratio | 14.89 | 9.55 |
| P/B ratio | 0.85 | 1.60 |
Profitability
| Metric | KROS | PRLD |
|---|---|---|
| Gross margin | 94.68% | 85.91% |
| Operating margin | 28.94% | -861.33% |
| Net margin | -553.88% | -269.75% |
| ROE | -31.70% | -45.23% |
| ROIC | -36.49% | -43.74% |
Growth (annualized)
| Metric | KROS | PRLD |
|---|---|---|
| Revenue CAGR (5Y) | 172.50% | N/A |
| Total return CAGR (5Y) | -21.98% | -33.98% |
Frequently asked
- How have KROS and PRLD total returns compared?
- Over the past 5 years, KROS delivered -21.98% and PRLD delivered -33.98% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Keros Therapeutics ROEPrelude Therapeutics ROEKeros Therapeutics operating marginPrelude Therapeutics operating marginKeros Therapeutics revenue growthPrelude Therapeutics revenue growthKeros Therapeutics free cash flowPrelude Therapeutics free cash flow
Keros Therapeutics & Prelude Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.